LIXT Lixte Biotechnology Holdings Inc.: Earnings per share for the last 12 months

Lixte Biotechnology Holdings (LIXT) - corporate logo

Lixte Biotechnology relies on outsourcing production and testing to maintain workforce flexibility. The company optimizes chemical supplies through a global network of laboratories, thereby reducing regulatory risks. Early-stage inhibitor development keeps finances aligned with R&D expenditures. On GURU.Markets, the annual growth of basic net income per share (TTM) shows that the parameter value is 22.80.

Lixte Biotechnology Holdings (LIXT) Earnings per share for the last twelve months: for the period 02/11/2024 - 07/06/2026

LIXT (Lixte Biotechnology Holdings): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price lixte.com|LIXT - Price Target Chart
- company stock capitalization data:
Market Capitalization Lixte Biotechnology Holdings Inc.|LIXT - Enterprise Value
- book capitalization indicators:
Accounting Value per Share Lixte Biotechnology|LIXT - Company Book Value|Market-to-Book Ratio lixte.com|LIXT - Aggregate Company Assets
- company total debt and liquidity indicators:
Debt to Equity Lixte Biotechnology|LIXT - Long-Term Debt to Equity|Current Liabilities to Capital Lixte Biotechnology, Inc.|LIXT - Company Aggregate Debts|Debt to Net Assets Lixte Biotechnology Holdings Inc.|LIXT - Company Long-Term Liabilities|Short-Term Debt Lixte Biotechnology|Intermediate Coverage Ratio lixte.com
- earnings and market multiples details:
LIXT - Net Income|Future Net Profit Lixte Biotechnology|LIXT - P/E Multiple|Future Price to Earnings Multiple Lixte Biotechnology Holdings Inc.|LIXT - PEG Multiple|Company Value to EBITDA Lixte Biotechnology Holdings Inc.|LIXT - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Lixte Biotechnology|LIXT - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth lixte.com|LIXT - Earnings per share growth in current year|Net earnings per share change forecast for next year Lixte Biotechnology
- revenue and sales details:
LIXT - Company Sales|Company Expected Sales Volume lixte.com|LIXT - Price-to-Revenue Ratio|Price-to-Projected Revenue Ratio Lixte Biotechnology Holdings Inc.
Fundamental company valuation:LIXT lixte.com
Flagship merchandise of Lixte Biotechnology Holdings, Inc.

The twelve-month earnings per share (EPS) trend measures the inertia of fundamental growth, reflecting the business's ability to scale net income relative to the volume of shares outstanding. By analyzing the current EPS YoY TTM growth rate, an investor can assess how geopolitical barriers in the scientific cooperation of Lixte Biotechnology (LIXT) impact the efficiency of oncology drug development, where any deceleration in the trend signals a risk of capital freeze.

Direct competitors

Net earnings per one share for the last twelve months incyte.com|HUTCHMED (HCM) - Earnings per share for the last twelve months|Earnings per share for the last 12 months NUVB|DAWN (Day One Bio) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Monopar Corp (MNPR)|Earnings per share for the last twelve months Inhibrx Biosciences (INBX)|IMAB - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Fennec Pharmaceuticals Inc. FENC|Heron - Earnings per share for the last twelve months|NVCT - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Coherus Biosciences|CRBP: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year Cardiff Oncology CRDF|Net earnings per share for the last 12 months BYSI|Net earnings per one share for the last twelve months BioAtla Corp BCAB|Net earnings per share for the last 12 months CTXR (Citius Pharmaceuticals)|CLRB (Cellectar Corp) - Earnings per share for the trailing year|BioLineRx Ltd. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters CANF (canfite.com)|Aprea - Net earnings per share (EPS TTM)|Earnings per share for the trailing year KZIA (Kazia Therapeutics)|SLXN: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months NuCana (NCNA)|Earnings per share for the last twelve months Chimerix, Inc.|CYCC: Earnings per share for the trailing year|Net earnings per share (EPS TTM) GTHX|Net earnings per share (EPS TTM) Kronos Bio Inc (KRON)|Earnings per share for the last twelve months Kintara KTRA|ONCT (Oncternal Corp) - Earnings per one share for the last 12 months|PRTG: Net earnings per share for the last 12 months